generics

Mylan and Pfizer roll out tricolor branding for their giant generics combo, Viatris
Mylan and Pfizer roll out tricolor branding for their giant generics combo, Viatris
Fierce Pharma
Mylan
Pfizer
Upjohn
M&A
generics
Viatris
branding
Flag link:
US warns that 2nd COVID-19 wave could worsen generic drug shortages
US warns that 2nd COVID-19 wave could worsen generic drug shortages
Beckers Hospital Review
generics
drug shortages
pandemic
COVID-19
Flag link:
Mylan, seeking to market Victoza generic, convinces panel to start up patent review
Mylan, seeking to market Victoza generic, convinces panel to start up patent review
Fierce Pharma
Mylan
patents
generics
Novo Nordisk
Victoza
diabetes
Flag link:
Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch
Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch
Fierce Pharma
Biogen
Tecfidera
Mylan
patents
generics
MS
multiple sclerosis
Flag link:
A new hope for Amarin? Vascepa generic settlement leaves analysts split on patent appeal success
A new hope for Amarin? Vascepa generic settlement leaves analysts split on patent appeal success
Fierce Pharma
Amarin
Vascepa
generics
Apotex
Flag link:
U.S. states accuse 26 drugmakers of generic drug price fixing in sweeping lawsuit
U.S. states accuse 26 drugmakers of generic drug price fixing in sweeping lawsuit
Reuters
price fixing
generics
drug pricing
Flag link:
FDA issues 69 new and revised draft product-specific guidances
FDA issues 69 new and revised draft product-specific guidances
RAPS.org
FDA
generics
Flag link:
FDA approves the first generic for Amarin's Vascepa — but is a launch imminent?
FDA approves the first generic for Amarin's Vascepa — but is a launch imminent?
Endpoints
FDA
Amarin
Vascepa
Hikma
generics
Flag link:
Bangladesh pharma claims to be first to launch generic remdesivir
Bangladesh pharma claims to be first to launch generic remdesivir
BioPharma Dive
Bangladesh
Beximco
generics
remdesivir
Gilead Sciences
COVID-19
Flag link:
Generic drugmaker Akorn files for bankruptcy
Generic drugmaker Akorn files for bankruptcy
Beckers Hospital Review
Akorn
generics
bankruptcy
Flag link:
Teva bails on price-fixing settlement in gamble on its role fighting COVID-19: report
Teva bails on price-fixing settlement in gamble on its role fighting COVID-19: report
Fierce Pharma
Teva Pharmaceutical
price fixing
generics
COVID-19
Sandoz
JNJ
Novartis
Taro Pharmaceuticals
Flag link:
What COVID-19 means for generics companies
What COVID-19 means for generics companies
Pharmaforum
COVID-19
pandemic
generics
Flag link:
Gilead inks deals with generics makers to supply COVID-19 therapy remdesivir for 127 countries
Gilead inks deals with generics makers to supply COVID-19 therapy remdesivir for 127 countries
Fierce Pharma
Gilead Sciences
generics
drug manufacturing
COVID-19
remdesivir
Flag link:
COVID-19 restrictions send generic drug shipping costs through the roof: survey
COVID-19 restrictions send generic drug shipping costs through the roof: survey
Fierce Pharma
COVID-19
generics
biosimilars
drug manufacturing
Flag link:
FDA guides generic drugmakers on bioequivalence study disruptions amid COVID-19
FDA guides generic drugmakers on bioequivalence study disruptions amid COVID-19
RAPS.org
FDA
generics
bioequivalence studies
COVID-19
pandemic
Flag link:
Mylan's Robert Coury returns to exec chairman role amid pandemic, delayed merger
Mylan's Robert Coury returns to exec chairman role amid pandemic, delayed merger
Beckers Hospital Review
Mylan
Robert Coury
Upjohn
generics
M&A
COVID-19
pandemic
Flag link:
FDA Offers Guidance for Generic Drug Developers of Hydroxychloroquine, Chloroquine
FDA Offers Guidance for Generic Drug Developers of Hydroxychloroquine, Chloroquine
RAPS.org
FDA
COVID-19
hydroxychloroquine sulfate
chloroquine phosphate
generics
Flag link:
Blackstone backs Alnylam with up to $2B investment
Blackstone backs Alnylam with up to $2B investment
BioPharma Dive
generics
Alnylam
Blackstone
RNAi
Flag link:
Former Novartis exec wants to repurpose generic drugs to fight Covid-19
Former Novartis exec wants to repurpose generic drugs to fight Covid-19
Stat
Axcella Health
WHO
Novartis
generics
drug repurposing
COVID-19
Flag link:
Novartis cancels $1B sale of generics after antitrust concerns forced delays
Novartis cancels $1B sale of generics after antitrust concerns forced delays
Endpoints
Novartis
generics
Sandoz
antitrust
Flag link:

Pages